Below are the most recent publications written about "Quinazolines" by people in Profiles.
-
Anderson EM, Lopez MF, Kastner A, Mulholland PJ, Becker HC, Cowan CW. The histone methyltransferase G9a mediates stress-regulated alcohol drinking. Addict Biol. 2022 01; 27(1):e13060.
-
Giordano A, Liu Y, Armeson K, Park Y, Ridinger M, Erlander M, Reuben J, Britten C, Kappler C, Yeh E, Ethier S. Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer. PLoS One. 2019; 14(11):e0224420.
-
Xiong H, Long H, Pan S, Lai R, Wang X, Zhu Y, Hill K, Fang Q, Zheng Y, Sha SH. Inhibition of Histone Methyltransferase G9a Attenuates Noise-Induced Cochlear Synaptopathy and Hearing Loss. J Assoc Res Otolaryngol. 2019 06; 20(3):217-232.
-
El-Mesallamy HO, El Magdoub HM, Chapman JM, Hamdy NM, Schaalan MF, Hammad LN, Berger SH. Biomolecular study of human thymidylate synthase conformer-selective inhibitors: New chemotherapeutic approach. PLoS One. 2018; 13(3):e0193810.
-
Högerle BA, Schneider M, Sudrow K, Souidi N, Stolk M, Werner I, Biermann A, Brockbank KGM, Stock UA, Seifert M. Effects on human heart valve immunogenicity in vitro by high concentration cryoprotectant treatment. J Tissue Eng Regen Med. 2018 02; 12(2):e1046-e1055.
-
Karsdal MA, Henriksen K, Nielsen MJ, Byrjalsen I, Leeming DJ, Gardner S, Goodman Z, Patel K, Krag A, Christiansen C, Schuppan D. Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy. Am J Physiol Gastrointest Liver Physiol. 2016 12 01; 311(6):G1009-G1017.
-
Phelps-Polirer K, Abt MA, Smith D, Yeh ES. Co-Targeting of JNK and HUNK in Resistant HER2-Positive Breast Cancer. PLoS One. 2016; 11(4):e0153025.
-
Williams CB, Soloff AC, Ethier SP, Yeh ES. Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting. Adv Cancer Res. 2015; 127:253-81.
-
Grek CL, Rhett JM, Bruce JS, Abt MA, Ghatnekar GS, Yeh ES. Targeting connexin 43 with a-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1. BMC Cancer. 2015 Apr 03; 15:296.
-
Yeh ES, Abt MA, Hill EG. Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors. Breast Cancer Res Treat. 2015 Jan; 149(1):91-8.